0001116463-26-000041
SEC filingQ1 results showed revenue decline and wider operating losses driven by international HCV softness and R&D investments, partially offset by gross margin gains from better mix and efficiencies, with cash burn improving on working capital timing.
OraSure Technologies reported Q1 FY2026 revenue of $27.9 million, down 6.7% from $29.9 million in the prior year quarter. This decrease stems largely from lower international HCV revenues, attributable to customer ordering patterns and funding constraints, as noted in management's discussion. Partially offsetting this topline pressure was growth in syphilis product sales to new customers in the women's health market, highlighting diversification efforts amid core diagnostic headwinds.
Gross profit totaled $11.8 million, a 4.0% decline from $12.3 million, yet gross margin expanded to 42.3%. This improvement reflects better fixed overhead absorption and a favorable product mix, including higher-margin non-product revenues. However, an increase in scrap expense during the quarter partially offset these gains, underscoring ongoing operational challenges in manufacturing efficiency.
Operating income deteriorated to -$23.3 million from -$17.8 million, a 31.1% worsening. The broader loss reflects the revenue shortfall combined with elevated operating expenses, particularly in R&D, against a backdrop of strategic investments in pipeline development. This dynamic illustrates the tension between near-term profitability and long-term innovation in the diagnostics space.
Net income was -$22.4 million or -$0.32 diluted EPS, compared to -$16.0 million or -$0.21 EPS last year, with the loss widening 39.5%. The deeper bottom-line impact ties to the operating shortfall and tax effects, including a decreased effective tax rate from increased valuation allowance on U.S. operations.
Cash flow from operations used $13.9 million, an improvement from $19.7 million, primarily due to working capital fluctuations driven by sales volumes, purchase patterns, inventory needs, and vendor terms. After $0.9 million in capital expenditures, free cash flow was -$14.8 million. Management affirms that existing cash and equivalents suffice to cover operating expenses and capex for at least the next twelve months, providing a liquidity buffer amid restructuring.
These results occur as OraSure navigates diagnostic market dynamics, with HCV timing issues and funding hurdles pressuring international sales, while women's health gains and margin discipline offer resilience. The company anticipates leveraging partnerships to expand low-cost diagnostic and molecular sample solutions globally, positioning for sustained operations.